By Fineline Cube 
Novartis AG (NYSE: NVS) announced that China’s National Medical Products Administration (NMPA) has granted approval for an additional indication for its Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy in adult patients with locally advanced or metastatic differentiated thyroid cancer harboring the BRAF V600E mutation who are radioactive iodine-refractory or ineligible and have failed prior VEGFR-TKI treatment, marking the fourth approved indication for this combination in China.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Novartis AG (NYSE: NVS) |
| Drug Combination | Tafinlar (dabrafenib) + Mekinist (trametinib) |
| Regulatory Authority | National Medical Products Administration (NMPA), China |
| Approval Type | New indication approval |
| Indication | BRAF V600E-mutated differentiated thyroid cancer, radioactive iodine-refractory, post-VEGFR-TKI failure |
| China Indications Total | Fourth approved indication for the combination |
| Trial Basis | Global Phase III multicenter study led by Chinese research center |
| Announcement Date | 11 Jun 2026 |
Clinical Trial Results & Efficacy Data
Primary Endpoint – Progression-Free Survival (PFS)
- Median PFS (Combo): 12.8 months
- Median PFS (Placebo): 3.7 months
- Improvement: +9.1 months absolute benefit
- Hazard Ratio: 0.38 (62% reduction in risk of progression or death)
- Statistical Significance: p < 0.001
Secondary Endpoint – Objective Response Rate (ORR)
- ORR (Combo): 57.4%
- ORR (Placebo): 3.8%
- Absolute Difference: +53.6 percentage points
- Clinical Significance: Substantial tumor shrinkage benefit demonstrated
Safety Profile
- New Safety Signals: None identified
- Safety Consistency: Consistent with established safety profile of the combination
- Overall Survival: Data immature but showing favorable trend
The pivotal Phase III trial featured broad Asian patient enrollment with leadership from a Chinese research center, ensuring regional relevance and regulatory acceptance. The study specifically addressed a high-unmet-need population of patients who had exhausted standard VEGFR-TKI therapies and were no longer candidates for radioactive iodine treatment.
Market Impact & Commercial Strategy
- Thyroid Cancer Market in China: Estimated 25,000-30,000 new differentiated thyroid cancer cases annually; BRAF V600E mutation present in approximately 40-45% of cases
- Target Population: Radioactive iodine-refractory patients represent 15-20% of BRAF-mutated cases, creating addressable population of 1,500-2,500 patients annually
- Competitive Positioning: First and only targeted therapy approved for this specific molecularly-defined, treatment-refractory population in China
- Pricing Strategy: Premium pricing reflecting significant clinical benefit and orphan-like market dynamics; estimated RMB 80,000-100,000 per month
- Revenue Potential: Peak annual sales projected at USD 120-180 million in China thyroid cancer indication alone
- Strategic Advantage: Fourth indication approval strengthens Novartis’s position in China’s precision oncology market and demonstrates commitment to addressing rare cancer subtypes
The approval reinforces Novartis’s leadership in BRAF/MEK inhibition and expands access to precision medicine for Chinese patients with molecularly-defined thyroid cancer subtypes who previously had limited therapeutic options.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial projections. Actual outcomes may differ due to competitive dynamics, pricing negotiations, and market adoption factors.-Fineline Info & Tech